Population Health Data:
Strengthening Decisions for Life Sciences SMEs
Earn a Certificate of Live Attendance
AI Webinar Explorer available after event
About this webinar
Life sciences small and medium-sized enterprises (SMEs) need to make high-stakes R&D decisions quickly, from understanding disease biology and validating biomarkers to identifying meaningful patient populations and generating evidence to support product development. Population-scale health data is creating new opportunities to answer these questions, without requiring SMEs to build equivalent research resources themselves. This webinar explores how SMEs can use population-scale health data to support evidence-driven decisions across the drug development lifecycle.
While population-scale health data offers significant potential, scale alone is not enough. The value of a population resource depends on whether it brings together the right populations, biological information, longitudinal health data and research capabilities to answer the evidence question at hand. Increasingly, the opportunity lies in connecting information across people, genetics, biology and time.
The featured panelists will explore how population-scale health data can be applied across the R&D lifecycle, from understanding disease and validating biomarkers to predicting risk, identifying meaningful subgroups and understanding outcomes over time. The session will also examine the questions SMEs should consider when evaluating a population research resource, helping teams begin with the evidence they need rather than simply the data available.
Register for this webinar to learn how SMEs can use population-scale health data to generate stronger evidence and inform research decisions.
Who should attend
- R&D and Scientific Leadership
- Translational Research and Precision Medicine
- Biomarker and Diagnostics R&D
- Genomics and Bioinformatics
- Data Science and AI/ML
- Epidemiology and Real-World Evidence
- Clinical Development
- Medtech and Digital Health R&D
What you will learn
- How population-scale health data can add value across the R&D lifecycle
- Why research strategies should start with the evidence question rather than the data available
- How linked genetic, biological and longitudinal data can support deeper research
- Practical applications including biomarkers, prediction, stratification and real-world outcomes
- How to assess whether a population research resource is suitable for a specific R&D question
Featured Speakers
Dr. Jared G. Maina
Jared Gichohi Maina is a genomics researcher investigating the biological and environmental determinants of complex human traits and diseases. His work spans statistical genetics, epidemiology and data science, with expertise in GWAS and post-GWAS analyses. He has a particular interest in improving the representation of globally diverse and historically underrepresented populations in genomics research.
He is currently a Research Associate at the Sandor Group, UK Dementia Research Institute, Imperial College London, where he applies genetics to drug repurposing. Using clinical cohorts such as the Parkinson’s Progression Markers Initiative (PPMI) alongside population cohorts like Our Future Health (OFH), his work investigates GLP-1 receptor agonists as potential therapeutics for Parkinson’s disease.
Kamil Lipinski
Kamil Lipinski is Director of Science and Molecular Epidemiology at Our Future Health, co-leading efforts to build one of the world’s largest and most diverse genomic and health-data resources. His work spans large-scale molecular data generation and translating population-level insights into research and clinical impact. Prior to this, he held senior roles in developing AI-driven molecular diagnostics at Evotec, an R&D CRO, and a biotech start-up DNAe. He specialises in scaling complex scientific programmes, integrating molecular data with advanced analytics, and enabling high-quality, ethically governed health data for discovery and innovation.
Helena Golaszewska, MPhil, BSc
Helena is a Lead Computational Biologist at OutSee, where she develops large-scale data analyses and statistical frameworks that use genetics and linked health data to investigate disease biology and prioritise therapeutic targets. She has worked across several major population and clinical resources, including Our Future Health, UK Biobank, FinnGen and Genomics England, and delivered genetic and multiomic analyses for OutSee’s work on the Longitude Prize on ALS. Helena holds an MPhil in Genomic Medicine from the University of Cambridge
Partner for this event
Our Future Health
Our Future Health is the world’s largest health research programme of its kind, on our way to bring together up to 5 million UK adults to revolutionise the way we fight disease. To date, we have recruited over 2.7 million participants, and by linking their health, lifestyle and genetic data, we offer a rich resource for researchers, enabling breakthroughs in early detection, prevention and treatment of diseases.